S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
Log in

NASDAQ:SAGESAGE Therapeutics Stock Price, Forecast & News

$50.00
-0.27 (-0.54 %)
(As of 08/14/2020 04:00 PM ET)
Add
Compare
Today's Range
$49.42
Now: $50.00▼
$50.97
50-Day Range
$41.13
MA: $45.56▼
$53.31
52-Week Range
$25.01
Now: $50.00▼
$173.76
Volume770,105 shs
Average Volume997,278 shs
Market Capitalization$2.60 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.68
Sage Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone that has completed Phase III clinical trials for the treatment of postpartum depression (PPD). The company's product pipeline also includes SAGE-217, a novel neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, bipolar depression, and sleep disorders; and SAGE-324, a novel neuroactive steroid that has completed Phase I clinical trials to treat various neurological conditions, including essential tremor and epileptiform disorders. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain; and SAGE-689, a novel GABAA receptor positive allosteric modulator that is in preclinical stage to treat acute and chronic CNS disorders. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of SAGE-217 in Japan, Taiwan, and South Korea. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Read More
SAGE Therapeutics logo

Beat the Market (BTM) Rank™

Analyst Opinion: 3.3Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.41 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SAGE
Previous Symbol
CUSIPN/A
CIK1597553
Webwww.sagerx.com
Phone617-299-8380

Debt

Debt-to-Equity Ratio0.03
Current Ratio12.77
Quick Ratio12.77

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$6.87 million
Price / Sales378.27
Cash FlowN/A
Price / Cash FlowN/A
Book Value$18.23 per share
Price / Book2.74

Profitability

EPS (Most Recent Fiscal Year)($13.38)
Net Income$-680,240,000.00
Net Margins-7,406.75%
Return on Equity-63.13%
Return on Assets-56.60%

Miscellaneous

Employees637
Outstanding Shares51,974,000
Market Cap$2.60 billion
Next Earnings Date11/10/2020 (Estimated)
OptionableOptionable
$50.00
-0.27 (-0.54 %)
(As of 08/14/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SAGE News and Ratings via Email

Sign-up to receive the latest news and ratings for SAGE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











SAGE Therapeutics (NASDAQ:SAGE) Frequently Asked Questions

How has SAGE Therapeutics' stock been impacted by COVID-19?

SAGE Therapeutics' stock was trading at $42.30 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, SAGE stock has increased by 18.2% and is now trading at $50.00.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of SAGE Therapeutics?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SAGE Therapeutics in the last year. There are currently 7 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for SAGE Therapeutics.

When is SAGE Therapeutics' next earnings date?

SAGE Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for SAGE Therapeutics.

How were SAGE Therapeutics' earnings last quarter?

SAGE Therapeutics Inc (NASDAQ:SAGE) announced its quarterly earnings results on Monday, August, 10th. The biopharmaceutical company reported ($2.63) EPS for the quarter, topping the consensus estimate of ($2.67) by $0.04. SAGE Therapeutics had a negative return on equity of 63.13% and a negative net margin of 7,406.75%. During the same period in the previous year, the business posted ($3.28) earnings per share.
View SAGE Therapeutics' earnings history.

What price target have analysts set for SAGE?

18 equities research analysts have issued 1-year target prices for SAGE Therapeutics' stock. Their forecasts range from $28.00 to $263.00. On average, they expect SAGE Therapeutics' share price to reach $82.26 in the next twelve months. This suggests a possible upside of 64.5% from the stock's current price.
View analysts' price targets for SAGE Therapeutics.

Has SAGE Therapeutics been receiving favorable news coverage?

News headlines about SAGE stock have trended somewhat negative recently, InfoTrie Sentiment reports. InfoTrie rates the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. SAGE Therapeutics earned a media sentiment score of -1.3 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days.
View the latest news about SAGE Therapeutics.

Who are some of SAGE Therapeutics' key competitors?

Some companies that are related to SAGE Therapeutics include Elanco Animal Health (ELAN), Dr.Reddy's Laboratories (RDY), Ono Pharmaceutical (OPHLF), Mylan (MYL), Ascendis Pharma A/S (ASND), Ionis Pharmaceuticals (IONS), Perrigo (PRGO), Emergent Biosolutions (EBS), Jazz Pharmaceuticals (JAZZ), ACADIA Pharmaceuticals (ACAD), Bausch Health Companies (BHC), Mirati Therapeutics (MRTX), Myokardia (MYOK), Ultragenyx Pharmaceutical (RARE) and United Therapeutics (UTHR).
View all competitors.

What other stocks do shareholders of SAGE Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other SAGE Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), AbbVie (ABBV), Alibaba Group (BABA), Gilead Sciences (GILD), Netflix (NFLX), Advanced Micro Devices (AMD), salesforce.com (CRM), Intercept Pharmaceuticals (ICPT) and QUALCOMM (QCOM).

Who are SAGE Therapeutics' key executives?

SAGE Therapeutics' management team includes the following people:
  • Dr. Jeffrey M. Jonas, CEO, Pres & Director (Age 66)
  • Ms. Kimi E. Iguchi, CFO & Treasurer (Age 57)
  • Dr. Albert J. Robichaud, Chief Scientific Officer (Age 58)
  • Ms. Anne Marie Cook, Sr. VP, Gen. Counsel & Sec. (Age 57)
  • Mr. Michael Cloonan, Chief Bus. Officer (Age 48)

What is SAGE Therapeutics' stock symbol?

SAGE Therapeutics trades on the NASDAQ under the ticker symbol "SAGE."

Who are SAGE Therapeutics' major shareholders?

SAGE Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include FMR LLC (15.00%), Vanguard Group Inc. (9.11%), Bellevue Group AG (2.72%), Victory Capital Management Inc. (1.89%), Goldman Sachs Group Inc. (1.57%) and Artal Group S.A. (0.45%). Company insiders that own SAGE Therapeutics stock include Albert Robichaud, Anne Marie Cook, James M Frates, Jeffrey M Jonas, Kimi Iguchi, Michael Cloonan, Stephen Kanes and Steven M Paul.
View institutional ownership trends for SAGE Therapeutics.

Which major investors are selling SAGE Therapeutics stock?

SAGE stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Artal Group S.A., Victory Capital Management Inc., Vanguard Group Inc., New York State Common Retirement Fund, Bank of America Corp DE, Cubist Systematic Strategies LLC, and Prudential Financial Inc..
View insider buying and selling activity for SAGE Therapeutics.

Which major investors are buying SAGE Therapeutics stock?

SAGE stock was acquired by a variety of institutional investors in the last quarter, including Asymmetry Capital Management L.P., Federated Hermes Inc., Goldman Sachs Group Inc., Point72 Asset Management L.P., PDT Partners LLC, Hudson Bay Capital Management LP, Russell Investments Group Ltd., and WINTON GROUP Ltd. Company insiders that have bought SAGE Therapeutics stock in the last two years include Albert Robichaud, and Jeffrey M Jonas.
View insider buying and selling activity for SAGE Therapeutics.

How do I buy shares of SAGE Therapeutics?

Shares of SAGE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is SAGE Therapeutics' stock price today?

One share of SAGE stock can currently be purchased for approximately $50.00.

How big of a company is SAGE Therapeutics?

SAGE Therapeutics has a market capitalization of $2.60 billion and generates $6.87 million in revenue each year. The biopharmaceutical company earns $-680,240,000.00 in net income (profit) each year or ($13.38) on an earnings per share basis. SAGE Therapeutics employs 637 workers across the globe.

What is SAGE Therapeutics' official website?

The official website for SAGE Therapeutics is www.sagerx.com.

How can I contact SAGE Therapeutics?

SAGE Therapeutics' mailing address is 215 FIRST STREET, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-299-8380 or via email at [email protected]

This page was last updated on 8/14/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.